INTRODUCTION
============

In the United States, nonalcoholic fatty liver disease (NAFLD) afflicts \~30% of the general population and is the leading cause of chronic liver disease.^[@bib1]^ NAFLD encompasses a broad spectrum of disorders, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD that can lead to cirrhosis,^[@bib2]^ hepatocellular carcinoma, and the need for transplantation.^[@bib3],\ [@bib4],\ [@bib5]^ Distinguishing between simple steatosis and NASH, as well as the staging of NASH fibrosis requires histologic diagnosis via liver biopsy. Biopsies are invasive, expensive, and can result in serious complications.^[@bib6]^ Furthermore, they are subject to sampling error and interobserver variability. Therefore, there exists a need for accurate, non-invasive, and cost-effective testing to assist in risk stratification of NASH.

Although hepatic steatosis is a hallmark of NAFLD, hepatic inflammation has a key role in the pathophysiology of NASH and fibrosis.^[@bib7]^ The cause of this inflammation has long been debated, and may be directly due to free fatty acid or cholesterol accumulation within hepatocytes,^[@bib8]^ microbial translocation from the gastrointestinal tract leading to intrahepatic immune cell activation,^[@bib9]^ or alterations in gut microbiota.^[@bib10]^ The ability to detect hepatic inflammation and distinguish steatosis from NASH non-invasively would allow for rapid diagnosis of NASH and monitoring of disease progression and response to therapy without the need for serial liver biopsies. Circulating monocyte-macrophage associated proteins might serve as biomarkers for NASH. CD163 is a hemoglobin scavenger receptor that is expressed by cells of the monocyte-macrophage lineage.^[@bib11]^ During cellular activation and inflammation, its soluble form (sCD163) is shed via proteolytic cleavage at the cell surface^[@bib12]^ and can be detected within serum or plasma. Kupffer cells, hepatic macrophages that have a key role in liver inflammation and fibrosis, express high levels of CD163 and represent over 80% of tissue macrophages,^[@bib13]^ raising the possibility that serum levels of sCD163 disproportionately reflect chronic hepatic inflammation. Indeed sCD163 has been examined in various liver conditions, including hepatitis C virus (HCV) and hepatitis B virus (HBV) infection. Recent work has shown sCD163 levels are elevated in patients with HCV-related cirrhosis compared with those with minimal or no fibrosis.^[@bib14]^ Soluble CD163 has also been shown to correlate with inflammation, specifically hepatic activity index, and fibrosis among patients with chronic hepatitis B and C.^[@bib15]^ In addition, in patients with cirrhosis of varying etiologies, elevated sCD163 levels are significantly associated with portal hypertension, Child-Pugh score, and model for end-stage liver disease score.^[@bib16],\ [@bib17]^ There is a paucity of data on sCD163 in NAFLD. One study of liver biopsies from children with NAFLD found an association between CD163 staining and the severity of steatosis and fibrosis.^[@bib18]^

Soluble CD14 (sCD14) is another more general marker of monocyte activation, lipopolysaccharide, and bacterial translocation. CD14 is expressed on Kupffer cells and hepatocytes,^[@bib19],\ [@bib20]^ and serum sCD14 is elevated in cirrhotic subjects with ascites and evidence of bacterial translocation.^[@bib21]^ In a recent study of 113 subjects with NAFLD sCD14 correlated with histologic evidence of inflammation and fibrosis.^[@bib22]^

To our knowledge, the roles of sCD163 and sCD14 have not been compared in liver disease, and more specifically have not been explored in NASH. We hypothesized that both sCD163 and sCD14 would correlate with hepatic inflammation and fibrosis, but sCD163 would have a stronger correlation with fibrosis and inflammation because of its relative specificity for the activation of Kupffer cells, which have a key role in liver injury and inflammation.

METHODS
=======

Cohort Selection
----------------

We performed a cross-sectional analysis of serum sCD163, sCD14, and hepatic histology. Liver biopsies and serum samples were obtained from patients undergoing gastric bypass surgery at Bon Secours Health System in Richmond, VA. This study was approved by the Bon Secours Health System and Partners Institutional Review Boards, and all patients gave written consent before participation. Standard of care core liver biopsies and serum samples were obtained at time of gastrbypass surgery. Inclusion criteria included age ≥18 years of age, liver biopsy at the time of surgery and ability to provide informed consent. Exclusion criteria included infection with HBV, HCV or HIV, or other causes of chronic liver disease and significant alcohol consumption (defined by \>1 drink/day in women or 2 drinks/day in men).

Liver biopsies were reviewed by a single blinded pathologist at Massachusetts General Hospital and scored for presence of fibrosis (modified Brunt stage, F0--F4) and assigned scores for grade of steatosis (grade 0=\<5% steatosis; 1=5--33% 2=34--66% 3=\>66%), hepatocyte ballooning (0=no ballooning; 1=few; 2=many), and lobular inflammation per 200 × (0=no foci; 1=\<2 foci; 2=2--4 foci; 3=\>4 foci).^[@bib23]^ Biopsies considered insufficient (\<15 mm in length or \<10 portal tracts) were excluded. NAFLD activity score (NAS) ranges from 0 to 8 and is a sum of the scores for steatosis grade, lobular inflammation, and hepatocyte ballooning. Baseline demographics, including age, gender, and race, as well as baseline clinical and laboratory values were collected on all patients.

Subjects were divided into four groups: Group 1, normal histology with NAS=0 and F=0, Group 2 (0\<NAS\<5, F\<3); Group 3, (NAS≥5, F\<3); and Group 4, advanced fibrosis (F≥3, any NAS).

NASH was defined based on the Clinical Research Network recommendations as having a score of 1 or greater in each of the three components of the NAS score: steatosis, hepatocyte ballooning, and lobular inflammation.^[@bib24]^ This definition provides similar categorization as the recently described FLIP algorithm,^[@bib25]^ but the decision tree was not used by pathologists during specimen analysis. Subjects were divided into three groups based on NASH: Group 1, normal, obese subjects (steatosis, lobular inflammation and hepatocyte ballooning all =0); Group 2, simple steatosis (steatosis score ≥1 with ballooning and/or lobular inflammation score \<1) and group ; Group 3, NASH (steatosis score ≥1, hepatocyte ballooning ≥1, and lobular inflammation ≥1).

Biochemical analysis
--------------------

For all but eight patients, blood draws occurred on the day of gastric bypass surgery when liver tissue was obtained; seven patients had blood drawn within six months before surgery and one patient had blood drawn within one year before surgery. Blood from one 10-ml EDTA-coated tube was separated by centrifugation and serum was stored at −80 °C. Samples were thawed and serum sCD163 and sCD14 levels were batch analyzed in duplicate using the Quantikine enzyme-linked immunosorbent assay system (R&D Systems, Minneapolis, MN). The mean assay coefficient of variance was 3.3% and 4.8% for sCD163 and sCD14, respectively.

Statistical analysis
--------------------

Data are distributed normally and are therefore presented as mean ± s.d. Differences between multiple groups were compared using one-way analysis of variance (or *χ*^2^ test, and differences between two specific groups were compared using unpaired Student\'s *t*-tests. Spearman\'s rank correlation was used to assess the relationship between sCD163 or sCD14 levels and histological fibrosis stage or NAS, whereas Pearson\'s correlation was used to assess the relationship between continuous variables.

Univariate and multivariate ordered logistic regression analyses were performed with NAS or fibrosis stage as dependent variables and sCD163 or sCD14 as explanatory variables. These models generated odds ratios for a given fibrosis stage or NAS corresponding to specific increases in sCD163 or sCD14. These models included age, gender, race, diabetes, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin as covariates.

We evaluated the prediction power of sCD163 plus ALT by calculating the receiver-operator characteristics (ROC) curves. We randomly partitioned the sample into two half-samples, each containing 50% of the cases (Group 3) and 50% of controls (Group 2). The first-half sample was used as the training set on which we fitted a logistic regression model and estimated the coefficients on sCD163 and ALT.^[@bib26]^ We used the second half-sample as the validation set and calculated the ROC curve of the score based on the coefficients estimated from the training set. We calculated the area under the ROC curve (AUROC) for both the training and validation sets. The software SAS, version 9.3 (SAS Institute Inc., Cary, NC) and SPSS version 17.0 (SPSS Inc., Chicago, IL) were used for the analyses. *P* values \<0.05 were considered significant.

RESULTS
=======

In this cohort, 145 patients who underwent gastric bypass surgery had samples available and were included in the analyses. There were 20 patients with normal liver histology (Group 1), 78 patients with NAS \<5, F\<3 (Group 2), 37 patients with NAS ≥5, F\<3 (Group 3), and 10 patients with advanced fibrosis or cirrhosis (Group 4). Subjects had NAS ranging from 0 to 7 and fibrosis stages ranging from 0 to 4.

The characteristics of the 145 patients and their respective groups are shown in [Table 1](#tbl1){ref-type="table"}. Patients with advanced fibrosis (Group 4) were more likely to be male, older, white, diabetic, and had significantly elevated ALT, AST, and total bilirubin compared with those with normal histology (Group 1). Differences in sCD163 and sCD14 levels between two groups are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"} online.

In a univariate ordered logistic regression model, age, male gender, white race, diabetes status, ALT, AST, sCD163 levels, and sCD14 levels all predicted increasing fibrosis stage (*P*\<0.05 for all analyses; results not shown). Similarly, diabetes status, male gender, white race, ALT, AST, and sCD163 levels predicted increasing NAS (*P*\<0.05 for all analyses; results not shown).

sCD163
------

Mean levels of sCD163 in Group 2 ([Figure 1](#fig1){ref-type="fig"}; 721 g/ml \[261\]), Group 3, (803 ng/ml \[350\]), and Group 4 (1031ng/ml \[529\]) differed significantly from controls ([Table 2](#tbl2){ref-type="table"}; Group 1, 552 ng/ml \[206\] *P*=0.009, *P*=0.005, and *P*=0.001, respectively) and across all groups (*P*=0.001). In addition, mean sCD163 levels were significantly elevated in the advanced fibrosis group vs. the steatosis group (*P*=0.003). In the univariate analysis, sCD163 correlated with both fibrosis stage and NAS ([Figure 2a](#fig2){ref-type="fig"}; *ρ*=0.277, *P*=0.001 and *ρ*=0.309, *P*\<0.001, respectively) and also correlated with each of the components of NAS, including steatosis (*ρ*=0.307, *P*\<0.001), lobular inflammation (*ρ*=0.177, *P*=0.033), and hepatocyte ballooning (*ρ*=0.296, *P*\<0.001, [Figure 3](#fig3){ref-type="fig"}). sCD163 also correlated with traditional biochemical markers of inflammation such as AST and ALT (*r*=0.295 and 0.356, respectively, *P*\<0.0001).

In a multivariable ordered logistic regression model of fibrosis that included age, gender, race, diabetes status, body mass index, ALT, AST, bilirubin, and sCD163, for every 100 ng/ml increase in sCD163 the odds ratiofor increasing fibrosis score was 1.16 (95% confidence interval (CI) 1.03--1.32, *P*=0.018). In this model, race and diabetes status also independently predicted increasing fibrosis ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Similarly, for every 100ng/ml increase in sCD163 the odds ratio for increasing NAS was 1.17 (1.04--1.32), *P*=0.010, and race, diabetes status, and body mass index also predicted increasing NAFLD activity ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}).

Moreover, sCD163 was an independent predictor of NAS ≥5 among patients without advanced fibrosis, as our sCD163-based predictive score (which included sCD163 and ALT levels) demonstrated an area under the receiver operating characteristic curve (AUROC) of 0.75 (95% CI: 0.61--0.88). The area under the ROC curve (AUROC) in the validation set was not different from the AUROC in the training set. [Figure 4a and b](#fig4){ref-type="fig"} show the ROC curves in the training set and the validation set, respectively. Only two variables, sCD163 and ALT were included in the model due to a limited sample size. When those with advanced fibrosis were included in the analysis, our sCD163-based predictive score demonstrated an AUROC of 0.76 (95% CI: 0.68--0.85) for NAS ≥5.

In a second analysis, there were 21 patients with normal liver histology (Group 5), 49 patients with steatosis (Group 6), and 75 patients with NASH (Group 7). The characteristics of the 145 patients and their respective groups are shown in [Table 2](#tbl2){ref-type="table"}. Diabetes status, gender, age, race, ALT, AST, sCD163, and sCD14 levels were significantly different between groups. Levels of sCD163 were significantly different between each group and are shown in [Figure 5](#fig5){ref-type="fig"}. Soluble CD163 levels were lower in normal individuals (mean 555 \[201\] ng/ml) compared with those with NAFLD (mean 691 \[270\] ng/ml, *P*=0.043) and NASH (mean 824 \[350\] ng/ml, *P*=0.001). Furthermore, sCD163 levels were significantly different between NASH subjects and those with steatosis (*P*=0.026). Our sCD163-based predictive score (which included sCD163 and ALT levels) demonstrated an area under the receiver operating characteristic curve (AUROC) of 0.70 (95% CI: 0.58--0.82) for the diagnosis of NASH (NASH vs. non NASH) and an AUROC of 0.66 (95% CI: 0.52--0.80) in a NASH vs. steatosis analysis. Furthermore, when the eight patients that did not have their blood drawn on day of gastric bypass were excluded, the NASH vs. non-NASH and NASH vs. steatosis AUROC improved to 0.73 (95% CI: 0.61--0.85) and 0.73 (95% CI: 0.60--0.86), respectively.

sCD14
-----

Mean sCD14 levels were elevated in Group 4 ([Figure 1](#fig1){ref-type="fig"}; 2111 ng/ml \[562\]) when compared with Groups 1 (1877 ng/ml \[336\]), 2 (1632 ng/ml \[497\]), and 3 (1706 ng/ml \[491) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}; *P*=0.065, *P*=0.004, and *P*=0.016, respectively). sCD14 levels differed significantly between the steatosis group and controls (*P*=0.040). In univariate analysis sCD14 differed significantly across groups ([Figure 1](#fig1){ref-type="fig"}, *P*=0.008, respectively).

In contrast to sCD163, sCD14 levels did not correlate with fibrosis stage or NAS ([Figure 2b](#fig2){ref-type="fig"}; *ρ*=0.139, *P*=0.095 and *ρ*=0.079, *P*=0.346, respectively) and did not predict increasing fibrosis stage or NAS in the ordered logistic regression model (results not shown).

DISCUSSION
==========

In this study, we found a significant association between sCD163, NASH, and fibrosis. This association remained significant after adjustment for age, gender, race, presence of diabetes, and aminotransferase levels; indeed, in a multivariate logistic regression model only sCD163, white race, and presence of diabetes were significantly associated with both NAS and fibrosis stage. In contrast another widely used circulating marker of macrophage activation, sCD14, was not associated with NAS or fibrosis stage, consistent with its reflection of overall macrophage status rather than liver specific status.

These data have significance for the understanding of the pathophysiology of NAFLD and fibrosis. First, the cohort of patients with NAS \<5 (Group 2) had significantly higher sCD163 than controls (Group 1), suggesting that early hepatic lipid accumulation may be associated with Kupffer cell activation and inflammation, even potentially before it is visible histologically. Second, the level of sCD163 was even higher in those with NAS ≥5 and higher yet in those with advanced fibrosis, suggesting ongoing and increasing Kupffer cell/macrophage activation throughout all stages of NAFLD. This activation persists even in those with advanced fibrosis. This confirms the recent study by Kazankov *et al.*^[@bib27]^who also found sCD163 to be elevated in NAS ≥5 compared with those with NAS\<5 as well as in patients with bridging fibrosis compared with lower fibrosis stages. Therefore, preventing or inhibiting Kupffer cell activation may be a rational therapeutic strategy for all stages of NAFLD.

The specific relationship between sCD163, fibrosis and NAS as compared with sCD14 is striking. Both are markers of macrophage activation, and both have been associated with tissue inflammation (e.g., carotid artery disease in HIV-HCV coinfection).^[@bib28]^ Although sCD14 has been associated with disease progression in HBV/HCV,^[@bib29]^ only sCD163 has been associated with fibrosis in HBV, HCV and HIV/HCV coinfection^[@bib14],\ [@bib15],\ [@bib30]^ as well as acute liver failure^[@bib31]^ and portal hypertension.^[@bib32]^ CD14 is a co-receptor for lipopolysaccharide along with toll-like receptor 4, and is expressed primarily on macrophages, but also neutrophils and dendritic cells. Its shed form, sCD14, appears to be a general marker of inflammation. In contrast, CD163 is highly expressed on Kupffer cells, and sCD163 is significantly higher in the hepatic veins compared with the portal veins.^[@bib17]^ Taken together these findings suggest that sCD163 is a marker of macrophage activation with a higher sensitivity for liver injury compared with other soluble markers. Soluble CD163 is not uniquely specific for the liver, however; elevated sCD163 is also associated with many conditions of immune activation: coronary plaque burden in HIV infection,^[@bib33]^ rheumatoid arthritis activity,^[@bib34]^ and, most interestingly in obesity.^[@bib35],\ [@bib36]^ The fact that in our study of obese patients sCD163 was further increased in those with significant liver disease demonstrates the potential utility of sCD163 in this population, and underlines the role of inflammation in the pathogenesis of NAFLD.

Although sCD163 alone cannot be used as a definitive diagnostic test for NASH, as part of a panel with other predictors of steatohepatitis, it may serve as a useful screening tool. Currently the American Association for the Study of Liver Disease practice guidelines suggest considering biopsy for NAFLD patients at the highest risk of developing NASH, based on the presence of metabolic syndrome and the NAFLD fibrosis score.^[@bib37]^ Another biomarker, circulating cytokeratin 18, has been suggested in one study to be markedly increased in NASH patients when compared with patients with simple steatosis (AUROC=0.82, 95% CI: 0.78--0.88),^[@bib4]^ but other studies have not corroborated its predictive value.^[@bib38]^

There are some limitations to this study. The data are cross-sectional, and therefore exploratory, as individuals were not followed after gastric bypass surgery. Further longitudinal data are required to determine whether sCD163 levels change with disease regression or progression. Our cohort was limited to those with obesity warranting weight loss surgery and further exploration of the value of sCD163 in non-obese individuals with NAFLD as well as in the general NAFLD population is needed. Nonetheless, levels of serum sCD163 in those with NAS=0 (Group 5) are similar to those reported in other "healthy control" groups,^[@bib39]^ supporting the role of sCD163 as a specific marker of hepatic inflammation. The use of obese controls in this study and including body mass index as a covariate aims to eliminate obesity as a potential confounder. Finally, only 10 subjects had advanced fibrosis, and 5 of these had NAS scores consistent with NASH, suggesting that the association of sCD163 and fibrosis scores may be confounded by concomitant steatohepatitis. However, previous studies^[@bib14],\ [@bib15]^ have reported a correlation between sCD163 and advanced fibrosis or cirrhosis.

Furthermore, although random division of the original cohort into a training and validation set for the AUROC analysis is a popular strategy when a true validation cohort is unavailable,^[@bib26]^ this method does not replace an independent validation cohort. Unfortunately, a true validation cohort was unavailable, so this strategy is our best attempt to reduce the bias associated with a single study cohort.

CONCLUSIONS
===========

In summary, serum sCD163, but not sCD14, correlated with overall NAS score, histologic elements of steatohepatitis, and fibrosis stage in patients with NAFLD. The assay for sCD163 is rapid, inexpensive, and highly reproducible. Measurement of sCD163 may have a role, together with other assessments, in the diagnosis and staging of NAFLD/NASH. Further studies addressing its prognostic value in other patient populations as well as the effect of therapeutic interventions (such as weight loss) are needed.

Study Highlights
================
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![Differences in soluble CD163 (sCD163) and sCD14 (sCD14) across all four groups. Although both sCD163 and sCD14 were significantly different across groups, only sCD163 increased across Group 1 to Group 4 and was significantly higher in all groups compared with controls. *P* values are for ANOVA. ANOVA, analysis of variance.](ctg201536f1){#fig1}

![(**a**) Soluble CD163 (sCD163) and (**b**) soluble CD14 (sCD14) compared with fibrosis stage and NAFLD Activity Score (NAS) score. Serum sCD163 correlated with both fibrosis stage and NAS score, whereas sCD14 did not. *P* values are for Spearman\'s rank correlation. NAFLD, nonalcoholic fatty liver disease.](ctg201536f2){#fig2}

![Association of soluble CD163 (sCD163) with each component of the nonalcoholic fatty liver disease Activity Score (NAS). Serum sCD163 correlated with all three individual components of the NAS---steatosis, lobular inflammation and ballooning. sCD14 did not (data not shown). *P* values are for Spearman\'s rank correlation.](ctg201536f3){#fig3}

![Training and validation receiver-operator characteristic (ROC) curves for model using sCD163 and alanine aminotransferase (ALT) as a predictor for nonalcoholic steatohepatitis (NASH). Receiver-operator characteristic (ROC) curves were obtained using sCD163 and ALT as a predictor for the presence of NASH in both a training (4A) and validation (4B) selection of patients from the cohort.sCD163, soluble CD163.](ctg201536f4){#fig4}

![Mean sCD163 levels across normal, steatosis, and NASH groups. *P*=0.001. NASH, nonalcoholic steatohepatitis.](ctg201536f5){#fig5}

###### Baseline characteristics of subjects

                             **Group 1 NAS=0, F=0 (*****n***=**20)**   **Group 2 0\<NAS\<5, F\<3 (*****n***=**78)**   **Group 3 NAS≥5, F\<3 (*****n***=**37)**   **Group 4 Any NAS, F≥3 (*****n***=**10)**   ***P*** **value**
  -------------------------- ----------------------------------------- ---------------------------------------------- ------------------------------------------ ------------------------------------------- -------------------
  Diabetes (*n*, %)          1 (5.0)                                   29 (37.2)                                      17 (45.9)                                  8 (80.0)                                    \<0.001
  Male (*n*, %)              1 (5.0)                                   14 (17.9)                                      9 (24.3)                                   5 (50.0)                                    0.028
  Smoker (*n*, %)            2 (10.0)                                  7 (9.0)                                        3 (8.1)                                    2 (20.0)                                    0.089
  White (*n*, %)             7 (35.0)                                  57 (75.0)[a](#t1-fn2){ref-type="fn"}           30 (81.1)                                  10 (100.0)                                  0.001
  Age (years)                39.6 (9.0)                                46.3 (11.4)                                    43.6 (11.6)                                55.7 (9.1)                                  0.002
  BMI (kg/m^2^)              46.3 (5.7)                                45.8 (6.8)                                     49.1 (7.9)                                 47.0 (4.2)                                  0.117
  ALT (IU/l)                 40 (29)                                   41 (17)                                        65 (31)                                    97 (86)                                     \<0.001
  AST (IU/l)                 17 (10)                                   23 (14)                                        38 (26)                                    66 (57)                                     \<0.001
  Total billirubin (mg/dl)   0.44 (0.25)                               0.48 (0.23)                                    0.49 (0.24)                                0.65 (0.28)                                 0.139
  sCD163 ng/ml               552 (206)                                 721 (261)                                      803 (350)                                  1031 (529)                                  0.001
  sCD14 ng/ml                1877 (336)                                1632 (497)                                     1706 (491)                                 2111 (262)                                  0.008

AST, aspartate aminotransferase; BMI, body mass index; F, modified brunt fibrosis score; NAS, Nonalcoholic fatty liver disease activity score. Data are mean (s.d.).

Two subjects missing race information.

###### Baseline characteristics of subjects

                             **Group 5 Normal (*****n***=**21)**   **Group 6 NAFLD (*****n***=**49)**   **Group 7 NASH (*****n***=**75)**   ***P*** **value**
  -------------------------- ------------------------------------- ------------------------------------ ----------------------------------- -------------------
  Diabetes (*n*, %)          2 (9.5)                               14 (28.6)                            39 (52.0)                           \<0.001
  Male (*n*, %)              1 (4.8)                               8 (16.3)                             20 (26.7)                           0.063
  Smoker (*n*, %)            3 (14.3)                              4 (8.2)                              7 (9.3)                             0.772
  White (*n*, %)             8 (38.1)                              38 (77.6)\*                          58 (77.3)                           0.003
  Age (years)                40.9 (10.7)                           46.9 (12.0)                          45.5 (11.1)                         0.130
  BMI (kg/m^2^)              46.4 (5.6)                            45.0 (6.6)                           49.1 (7.9)                          0.048
  ALT (IU/l)                 39 (29)                               42 (26)                              60 (40)                             0.006
  AST (IU/l)                 18 (10)                               24 (20)                              35 (29)                             0.006
  Total billirubin (mg/dl)   0.46 (0.26)                           0.47 (0.20)                          0.50 (0.26)                         0.675
  sCD163 ng/ml               555 (201)                             691 (270)                            824 (350)                           0.001
  sCD14 ng/ml                1901 (347)                            1554 (411)                           1773 (524)                          0.007

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index. Data are mean (s.d.). *P* values are for *χ*^2^ test or unpaired *t*-test.
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